Michelson Diagnostics releases preliminary specification for handheld OCT probe

16 January 2009

UK company Michelson Diagnostics has issued a preliminary specification for its clinical optical coherence tomography (OCT) probe and processing system, which the company says is planned for launch in late spring this year. The new OCT system has been given the name Vivosight.

Two variants of the new Vivosight probe are specified, one is a version with X-Y scanning, to enable 3D mapping of flat tissue such as skin, and the other is a version equipped with a rigid endoscope, suitable for internal applications. The unique multi-beam design provides double the image resolution (ie better than 10 μm) available from conventional single-beam designs, resulting in crisper, clearer OCT images, showing more clinical detail.

“We will be applying for a CE-mark for the product, which will enable sales for clinical use in Europe, in the spring 2009 time-frame.” said Jon Holmes, Chief Executive, “This will be followed by a 510(k) for the
equivalent in the US market.”

Michelson Diagnostics is applying multi-beam OCT to the diagnosis, monitoring and treatment of cancer, particularly dermal and oral cancer. The company says it is working closely with leading clinicians,
who believe that multi-beam OCT, by providing a new, detailed window into the body, will accelerate the care of cancer, enabling faster, more accurate treatment that will save lives and produce substantial cost savings to the medical services.

Michelson Diagnostics will be exhibiting a prototype version of the instrument on stand 8731 at BIOS09, San Jose, USA 24-25 January 2009.

Bookmark this page

Your browser does not support inline frames or is currently configured not to display inline frames.	Your browser does not support inline frames or is currently configured not to display inline frames. Michelson Diagnostics releases preliminary specification for handheld OCT probe 16 January 2009 UK company Michelson Diagnostics has issued a preliminary specification for its clinical optical coherence tomography (OCT) probe and processing system, which the company says is planned for launch in late spring this year. The new OCT system has been given the name Vivosight. Two variants of the new Vivosight probe are specified, one is a version with X-Y scanning, to enable 3D mapping of flat tissue such as skin, and the other is a version equipped with a rigid endoscope, suitable for internal applications. The unique multi-beam design provides double the image resolution (ie better than 10 μm) available from conventional single-beam designs, resulting in crisper, clearer OCT images, showing more clinical detail. “We will be applying for a CE-mark for the product, which will enable sales for clinical use in Europe, in the spring 2009 time-frame.” said Jon Holmes, Chief Executive, “This will be followed by a 510(k) for the equivalent in the US market.” Michelson Diagnostics is applying multi-beam OCT to the diagnosis, monitoring and treatment of cancer, particularly dermal and oral cancer. The company says it is working closely with leading clinicians, who believe that multi-beam OCT, by providing a new, detailed window into the body, will accelerate the care of cancer, enabling faster, more accurate treatment that will save lives and produce substantial cost savings to the medical services. Michelson Diagnostics will be exhibiting a prototype version of the instrument on stand 8731 at BIOS09, San Jose, USA 24-25 January 2009. Bookmark this page Your browser does not support inline frames or is currently configured not to display inline frames. To top	Your browser does not support inline frames or is currently configured not to display inline frames.